Subscribe
Subscribe

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Medulloblastoma orphan drug designation for Oncurious

Market Access – the pitfall where innovations go lost

Market access is a crucial turning point for many companies. Getting your drug reimbursed by the government means the world. However, gaining market access [...]

Better together: R&D and GMP analytics teamed up at anaRIC Biologics

Coris Bioconcept diagnoses antibiotic resistance

With almost 20 years of experience, Coris BioConcept knows the world of infectious disease diagnostics inside and out. Their straightforward chromatography-based [...]

Legislators finally embrace in silico trials

In silico analysis is a natural complement to in vivo and in vitro testing. It uses engineering simulation to create reliable, computer-based models that predict [...]

PharmaFluidics raises 2.7 million euro to commercialize novel micro-chip device

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 2.7 million euro of additional funding.

Survivors’s plasma to treat ebola patients does not meet expectations

Ebola Tx is the largest clinical study ever performed with blood plasma of people that survived Ebola, to treat the disease. The study was performed in Guinea by the Institute of Tropical Medicine (ITM) in Antwerp. The results of the study, which took place in 2015 during the  Ebola epidemic, not only show that this treatment is feasible, but also that it presents no risk. The treatment causes very few side effects. However, the effectiveness needs to be further examined.

Mosquito Wars

Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.

Ablynx initiates Phase IIb study of inhaled anti-RSV nanobody

ViroVet successfully raises €5 million in series A funding

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Medulloblastoma orphan drug designation for Oncurious

Market Access – the pitfall where innovations go lost

Market access is a crucial turning point for many companies. Getting your drug reimbursed by the government means the world. However, gaining market access [...]

Better together: R&D and GMP analytics teamed up at anaRIC Biologics

Coris Bioconcept diagnoses antibiotic resistance

With almost 20 years of experience, Coris BioConcept knows the world of infectious disease diagnostics inside and out. Their straightforward chromatography-based [...]

Legislators finally embrace in silico trials

In silico analysis is a natural complement to in vivo and in vitro testing. It uses engineering simulation to create reliable, computer-based models that predict [...]

PharmaFluidics raises 2.7 million euro to commercialize novel micro-chip device

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 2.7 million euro of additional funding.

Survivors’s plasma to treat ebola patients does not meet expectations

Ebola Tx is the largest clinical study ever performed with blood plasma of people that survived Ebola, to treat the disease. The study was performed in Guinea by the Institute of Tropical Medicine (ITM) in Antwerp. The results of the study, which took place in 2015 during the  Ebola epidemic, not only show that this treatment is feasible, but also that it presents no risk. The treatment causes very few side effects. However, the effectiveness needs to be further examined.

Mosquito Wars

Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.

Ablynx initiates Phase IIb study of inhaled anti-RSV nanobody

ViroVet successfully raises €5 million in series A funding